- Home
- EXP vs MIRM Comparison
EXP vs MIRM Comparison
Compare EXP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXP | MIRM |
|---|---|---|
| Founded | 1963 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.7B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EXP | MIRM |
|---|---|---|
| Price | $220.47 | $101.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $227.11 | $119.85 |
| AVG Volume (30 Days) | 348.8K | ★ 1.0M |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 13.16 | N/A |
| Revenue | ★ $495,023,000.00 | $19,138,000.00 |
| Revenue This Year | $1.97 | $26.22 |
| Revenue Next Year | $1.95 | $22.04 |
| P/E Ratio | $16.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $171.99 | $43.50 |
| 52 Week High | $243.64 | $114.99 |
Technical Indicators
Market Signals| Indicator | EXP | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 67.78 | 51.95 |
| Support Level | $202.60 | $95.68 |
| Resistance Level | $224.06 | $107.51 |
| Average True Range (ATR) | 7.52 | 5.22 |
| MACD | 1.93 | -0.65 |
| Stochastic Oscillator | 91.13 | 33.42 |
Price Performance
Historical ComparisonAbout EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.